The National Health Surveillance Agency (Anvisa) issued an alert about the falsification of batches of Botox 100U, a medicine based on botulinum toxin A, used for aesthetic and therapeutic purposes. The communiqué was published this Thursday (5) in a note on the entity’s official website.
According to the agency, cases of adulteration of batches C7654C3F and C6835C3 of the Botox 100U product were identified, which are labeled in Portuguese and Turkish, respectively. These identifications were verified by the regulator’s agents in ports, airports and border areas.
The company Allergan Produtos Farmacêuticos Ltda., holder of the drug registration, confirmed that these batches are fake and that they were not imported into Brazil by official means.
Anvisa advises health professionals and the population not to use the counterfeit product and to immediately notify the agency, through its service channels, if they identify adulterated products.
The entity also determined the seizure and prohibition of the sale, distribution and use of counterfeit lots, through resolutions published in the Official Gazette (DOU). Drug counterfeiting is a crime that puts people’s health at risk and can cause irreversible or even fatal damage.
The health authority recommends that consumers purchase medicines only at establishments authorized by the health surveillance and that they check the origin, validity, sealing and labeling of the products. In addition, it is important to always demand the invoice and consult the doctor before starting any treatment.
See counterfeit products below:
